Athira Pharma Inc. Common Stock (NASDAQ: ATHA)
The Complaint alleges that during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: the research conducted by the individual Defendants, which formed the foundation for Athira’s product candidates and intellectual property, was tainted by scientific misconduct, including the manipulation of key data; and (2) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and omitted material facts necessary in order to make the statements made not misleading.